Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
about
Effect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI StudiesFuture clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophreniaA mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment.Nicotinic ACh receptors as therapeutic targets in CNS disordersnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersNeurophysiological models for new treatment development in schizophrenia: early sensory approaches.Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia.Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia.Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study.Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in SchizophreniaAQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment.The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.The effect of α7 nicotinic receptor activation on glutamatergic transmission in the hippocampus.Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands.Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerLatest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.Emerging drugs for schizophrenia: an update.Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.Drug repurposing and emerging adjunctive treatments for schizophrenia.Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomographyThe therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's DiseaseWhat is the promise of nicotinergic compounds in schizophrenia treatment?Improving Current Treatments for Schizophrenia.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled TrialsA Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system.
P2860
Q26744718-4E59F8FE-2FB9-4AC9-A274-53CAE73981CEQ27014120-086444E9-1C84-4361-87FC-55476744735DQ27324628-27DF078A-C01B-4280-805D-C74F413C82D3Q28111941-322EB622-6216-4A5C-BD17-C52D83BD927BQ30362464-AAD0528B-3EF7-4216-8DF2-BCDE825F4880Q30372351-33775570-1616-419F-BBF9-CA1322FD902BQ30384452-4E93D1D3-6415-4EB3-A3A2-5376837348DAQ30387378-1BA3F778-8796-41A4-AF6D-32850484318DQ30394589-79F05FF5-AF9F-4AA6-A2F0-9E9232092B71Q30426629-80A2619C-66F1-4CD4-B078-2B89DC93B45DQ33933877-EFB63CB0-9505-4001-A3C6-C1C71D5E9785Q34458090-26B206BD-87FF-4018-AB54-E41078B99F31Q34481351-F11C4668-6773-4038-A7EB-2828335B0EB3Q35111465-E1187EA4-9D13-444F-9A93-DB370921F6CAQ35733853-493E6819-8D51-4D67-96B3-114BF01CD8D0Q36088364-3C08A15B-8554-4990-9A4B-225B25DEAB2FQ36144877-ED2B8849-0E80-4C8A-905C-C67CEA2674A8Q36213170-3B3D9D3B-1163-4699-AEDF-133DB1D3EE15Q36243977-74B0183E-4565-4DA7-BD9A-8CC7DDC26EEBQ36287717-A2FBCDA2-71C2-4142-AEE2-6047A68B831CQ37258840-D5DDB039-30AB-4EDB-B8FA-16EE41CC2314Q38225930-8B847EB2-3490-495C-BFD6-00E585866E75Q38252404-BBFDC31B-9E98-40AD-A043-EF3884292129Q38286246-9B7F7243-6B14-42B5-9E30-AE071551F787Q38417631-5D10D90C-643D-4A58-9933-8CA1D36A9ECFQ38558845-D2119250-5A6D-40A0-8F63-1FC7407DD255Q38560778-035C2483-559D-4353-8401-FE979D1C2D39Q38699013-15D424F3-6A3B-4972-8C71-89CFE62D8EF0Q38788038-C3F15674-F97F-4901-A7DE-8CA31D1FF9A2Q38811805-F9718A61-E84C-4D6C-9AFD-5AA7C350F771Q38955513-D5530E95-7DE8-45C6-B6D1-17F19BBF1E74Q39233330-AC1C6798-DB6E-4BED-9320-A6E384333081Q39261867-D626F52D-854C-46BD-B951-B430A784BA8EQ41456540-FDAB3778-03CE-4684-90C4-9E7BB376FA71Q41687338-20AD3151-8CF7-4E80-A23C-B1DD0C1ACE49Q45961748-B0BD505C-57B0-49E8-AB6B-6FF170E527F8Q46315298-B637BD29-F1A5-4C8C-882C-7166AD27514DQ47158626-97F76CA9-20BC-43E4-84A4-BCAC0F74F8B9Q48785714-9D3D3E70-6CA2-4520-A9B0-B8058DFF5D9EQ50345655-72F64D7D-8C86-4998-BC55-85BF1AB68ABC
P2860
Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@ast
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@en
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@nl
type
label
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@ast
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@en
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@nl
prefLabel
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@ast
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@en
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@nl
P2093
P1476
Normalizing effects of EVP-612 ...... n patients with schizophrenia.
@en
P2093
Dana C Hilt
Lance O Bauer
Maria Gawryl
Michael Palfreyman
Nancy Dgetluck
Sheldon H Preskorn
P356
10.1097/01.PRA.0000442935.15833.C5
P577
2014-01-01T00:00:00Z